Akcea Therapeutics Inc

Most Recent

  • uploads///dna _
    Company & Industry Overviews

    Why Alnylam Pharmaceuticals Stock Rose ~16% Yesterday

    Yesterday, Alnylam Pharmaceuticals (ALNY) closed the day ~16.3% higher than the previous day’s closing price.

    By Sarah Collins
  • uploads///medications __
    Company & Industry Overviews

    Why Citius Pharmaceuticals Stock Rose 31% in Week Ended July 13

    In the week ended July 13, Citius Pharmaceuticals (CTXR) stock rose 31% to $3.09, from $2.35 on July 6. Since July 10, it has grown consistently.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Must-Know Developments for Ionis Pharmaceuticals in 2018

    On February 20, 2018, Ionis announced that the company has licensed the drug IONIS-AZ5-2.5Rx to AstraZeneca (AZN).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Key Updates on Akcea Therapeutics’ Volanesorsen

    Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug for the treatment of familial chylomicronemia syndrome (or FCS) and familial partial lipodystrophy (or FPL).

    By Mike Benson
  • uploads///AKCA
    Company & Industry Overviews

    Exploring the Financial Performance of Akcea Therapeutics

    In 2017, Akcea Therapeutics (AKCA) generated total revenue of $55.2 million.

    By Kenneth Smith
  • uploads///AKCA
    Company & Industry Overviews

    A Look at Akcea Therapeutics’ Product Pipeline

    Akcea Therapeutics’ (AKCA) Volanesorsen is currently under review in the United States, the European Union, and Canada.

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    Analysts’ Recommendations for Akcea and Its Peers in March

    Akcea Therapeutics is currently advancing a mature pipeline of four novel drugs with the potential to treat many cardiometabolic diseases.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.